Starpharma and Lilly sign new drug delivery collaboration
Monday, 01 February, 2010
Starpharma (ASX:SPL) announced today it has signed an agreement with U.S.-based Eli Lilly and Company, which will use Starpharma's dendrimer drug delivery technology in its human pharmaceutical line.
Dendrimers are synthetic molecules that can be built from the ground up to have specific chemical properties and can be used for the production of pharmaceuticals.
As a part of the agreement Lilly will fund a collaborative research and development programme with the aim of creating improved drugs using dendrimer technology, which will then be commercialised by Lilly.
Starpharma already has an agreement with Lilly, signed in May 2009, for the development of animal health products.
Starpharma (ASX:SPL) experienced a strong year in 2010, rising 231%, and is trading at 73c as of midday, up 2.8% for the day.
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
